Congress meeting · Dr. Rosa Kimura

29 May 2026 · In person · Dr. Rosa Kimura, Christie NHS Foundation Trust · MSL Mei Tanaka · Vantrexa

ReviewedVeeva CRMENG-0115—

Capture insight from this engagement

Location: Christie NHS Foundation Trust
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: MTMei TanakaMSL, Oncology (Japan)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround
Duration of response
Elderly / ECOG 2 patients

Scientific content used

PD-L1 testing pathway infographic

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?
How should grade 2 infusion reactions be managed without steroids?

Notes

Congress meeting with oncology pharmacist at Christie NHS Foundation Trust. Discussed pd-l1 testing turnaround, duration of response, elderly / ecog 2 patients.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 3
Depth of exchange: 2
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0115

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
04 Sept 2026, 13:20 UTC	Update	RARachel Adeyemi	progress	Draft → Submitted	—	UI